Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
8.49
-0.25 (-2.86%)
Nov 2, 2026, 4:00 PM EST - Market closed
Benitec Biopharma Employees
Benitec Biopharma had 24 employees as of June 30, 2026. The number of employees increased by 5 or 26.32% compared to the previous year. That makes Benitec Biopharma the 37,806th largest employer in the world and 5,381st in the United States.
Employees
24
Change (1Y)
5
Growth (1Y)
26.32%
Revenue / Employee
n/a
Profits / Employee
-$1,897,750
Market Cap
296.15M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 24 | 5 | 26.32% |
| Jun 30, 2025 | 19 | 3 | 18.75% |
| Jun 30, 2024 | 16 | -2 | -11.11% |
| Jun 30, 2023 | 18 | 0 | - |
| Jun 30, 2022 | 18 | 4 | 28.57% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Enanta Pharmaceuticals | 120 |
| Arcturus Therapeutics Holdings | 111 |
| Alector | 103 |
| SAB Biotherapeutics | 86 |
| Scribe Therapeutics | 82 |
| Agenus | 81 |
| Opus Genetics | 28 |
| vTv Therapeutics | 26 |
BNTC News
- 5 days ago - Benitec Biopharma announces interim results from BB-301 trial - TheFly
- 5 days ago - Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 - GlobeNewsWire
- 10 days ago - Benitec Biopharma initiated with an Outperform at Raymond James - TheFly
- 13 days ago - Benitec Biopharma Proxy statement: Proxy filing - Filings
- 13 days ago - Benitec Biopharma Proxy statement: Proxy filing - Filings
- 4 weeks ago - Benitec Biopharma says BB-301 pivotal still on track for mid-2027 - TheFly
- 4 weeks ago - Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study - GlobeNewsWire
- 6 weeks ago - Benitec Biopharma price target raised to $17 from $16 at Wedbush - TheFly